^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    21h
    TAK-012-1501: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=16, Terminated, Takeda | Trial completion date: May 2026 --> Nov 2025 | Active, not recruiting --> Terminated; Sponsor decision (No safety concern)
    Trial completion date • Trial termination
    |
    cyclophosphamide • fludarabine IV • TAK-012
    1d
    Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC (clinicaltrials.gov)
    P1, N=20, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Recruiting | N=13 --> 20 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment open • Enrollment change • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    1d
    Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial. (PubMed, Blood)
    The phase 3 CLL13/GAIA trial assesses three time-limited combinations: venetoclax-rituximab (RV), venetoclax-obinutuzumab (GV), and venetoclax-obinutuzumab-ibrutinib (GIV) compared to chemoimmunotherapy (CIT). Fit patients with CLL without TP53 aberrations were randomized between six cycles of CIT (fludarabine-cyclophosphamide-rituximab [FCR], bendamustine-rituximab [BR]) or 12 cycles of RV, GV or GIV (GIV: ibrutinib continuation until cycle 36 if measurable residual disease [MRD] at months 12/15)...In the GIV arm, clinically relevant QoL improvements occurred later (month 15, after the end of treatment in most patients) than with GV/RV, likely due to a higher treatment-related symptom burden. The trial is registered at clinicltrial.gov with the identifier, NCT02950051.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • bendamustine • fludarabine IV
    1d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    2d
    PNOC018: Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    H3.3K27M
    |
    cyclophosphamide • fludarabine IV • KIND T
    2d
    A Phase I Study of BEN301 Injection in the Treatment of Autoimmune Diseases (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Beijing Boren Hospital
    New P1 trial
    |
    CRP (C-reactive protein)
    |
    cyclophosphamide • fludarabine IV
    2d
    Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=59, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    sirolimus • melphalan • fludarabine IV • itacitinib (INCB039110)
    2d
    P30CA015704: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=61, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    3d
    DUAL-NK-NB: Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    3d
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Peking University People's Hospital | N=30 --> 50 | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    3d
    DUET-HCC: Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    CD276 (CD276 Molecule) • GPC3 (Glypican 3)
    |
    cyclophosphamide • fludarabine IV
    3d
    Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant (clinicaltrials.gov)
    P1, N=30, Suspended, University of Chicago | Recruiting --> Suspended
    Trial suspension
    |
    melphalan • fludarabine IV